IBRX270115P00020000
IBRX Jan 15 2027 20.00 Put
optionOPRA
EODOct 14, 2026
11.40USD-13.636%(-1.80)20Vol23OI
Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
20
Expiration
Jan 15, 2027
DTE
87d
Moneyness
ITM
Intrinsic
$11.52
IBRX 20 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | — | — | 0 | 0 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | — | — | 0 | 0 |
| Nov 13, 2026 | 24d | — | — | 0 | 0 |
| Nov 20, 2026 | 31d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $11.40 | -13.64% | 20 | 23 |
| Mar 19, 2027 | 150d | — | — | 0 | 0 |
| Apr 16, 2027 | 178d | — | — | 0 | 0 |
| May 21, 2027 | 213d | — | — | 0 | 0 |
| Aug 20, 2027 | 304d | — | — | 0 | 0 |
| Nov 19, 2027 | 395d | $11.10 | +0.00% | 1 | 1 |
| Jan 21, 2028 | 458d | $14.10 | +6.82% | 2 | 37 |
| Mar 17, 2028 | 514d | — | — | 0 | 0 |
| Jan 19, 2029 | 822d | — | — | 0 | 0 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.